Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

On October 21, 2021 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in Washington, D.C., from November 10-14, 2021 (Press release, Imvax, OCT 21, 2021, View Source;utm_medium=rss&utm_campaign=imvax-to-present-preclinical-data-on-igv-001-mechanism-of-action-at-sitc-annual-meeting [SID1234596598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster highlights recent preclinical data for the company’s most advanced product candidate, IGV-001. The data elucidate potential mechanisms for the observed immune-stimulating and tumor-suppressing activity of IGV-001 seen in the Phase 1 clinical study for glioblastoma.

"We’re pleased to share new insights into the mechanism of action of IGV-001, which are supportive of the clinical efficacy data we’ve previously reported," said John Furey, Chief Executive Officer. "These insights are valuable both as we prepare for a Phase 2b trial in glioblastoma and as we expand our platform to address other solid tumor types."

Details of the poster presentation are as follows:

Title: Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses

Number: P218

Timing: November 13, 2021, 7:00 a.m-8:30 p.m. EST

Presenter: Mark Exley, Ph.D., Chief Scientific Officer